Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

Katrin Teich; Julia Krzykalla; Silke Kapp-Schwoerer; Verena I Gaidzik; Richard F Schlenk; Peter Paschka; Daniela Weber; Walter Fiedler; Michael W M Kühn; Thomas Schroeder; Karin Mayer; Michael Lübbert; Dhanya Ramachandran; Axel Benner; Arnold Ganser; Hartmut Döhner; Michael Heuser; Konstanze Döhner; Felicitas Thol

doi:10.3324/haematol.2021.278894

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

Haematologica. 2021 Nov 1;106(11):2986-2989. doi: 10.3324/haematol.2021.278894.

Authors

Katrin Teich¹, Julia Krzykalla², Silke Kapp-Schwoerer³, Verena I Gaidzik³, Richard F Schlenk⁴, Peter Paschka³, Daniela Weber³, Walter Fiedler⁵, Michael W M Kühn⁶, Thomas Schroeder⁷, Karin Mayer⁸, Michael Lübbert⁹, Dhanya Ramachandran¹⁰, Axel Benner², Arnold Ganser¹, Hartmut Döhner³, Michael Heuser¹, Konstanze Döhner³, Felicitas Thol¹

Affiliations

¹ Department of Hematology, Hemostaseology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover.
² Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg.
³ Department of Internal Medicine III, University Hospital of Ulm, Ulm.
⁴ Nationales Centrum für Tumorerkrankungen Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg.
⁵ Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg.
⁶ Department of Hematology, Medical Oncology and Pneumology, University Medical Center Mainz, Mainz.
⁷ Department of Hematology, Oncology, and Clinical Immunology, University of Düsseldorf, Medical Faculty, Düsseldorf.
⁸ Internal Medicine III, University Hospital of Bonn, Bonn.
⁹ Klinik für Innere Medizin I, Universitätsklinikum Freiburg, Faculty of Medicine, Freiburg.
¹⁰ Department Molecular Gynecology, Hannover Medical School, Hannover.

No abstract available

MeSH terms

Aminoglycosides / therapeutic use
Gemtuzumab
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Polymorphism, Single Nucleotide*
Sialic Acid Binding Ig-like Lectin 3 / genetics

Substances

Aminoglycosides
Sialic Acid Binding Ig-like Lectin 3
Gemtuzumab

Grants and funding

Funding: this study was supported by grant DJCLS R13/14 from the Deutsche José Carreras Leukämie-Stiftung e.V., grant 01GM1909A from the German Federal Ministry of Education and Research and by Sonderforschungsbereich SFB 1074, project B3 (to KD) from the Deutsche Forschungsgemeinschaft.